Gubra AS (OCSE:GUBRA) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:GUBRA Gubra AS OCSE:GUBRA
68 GF Score
Price kr360.80
GF Value kr196.36
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Gubra AS Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

OCSE:GUBRA
68GF Score
Gubra AS OCSE:GUBRA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gubra AS (OCSE:GUBRA) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be overvalued. The current stock price of kr360.80 is trading 83.7% above its estimated GF Value™ of kr196.36. GuruFocus considers Gubra AS to be Significantly Overvalued.

Key valuation signals for OCSE:GUBRA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr196.36 vs. price of kr360.80 (83.7% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the OCSE:GUBRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gubra AS Business Description

Other Exchanges PI3:Germany
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
68GF Score

Get the complete analysis for OCSE:GUBRA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr360.80
Price
kr196.36
GF Value